SCHEMBL17628573

SCHEMBL17628573

CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccc3)cc2)c2ncn(C(C)C)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 1.00
CCNE1 P24864 9/20 1.00
CCNK O75909 7/20 1.00
CDK12 Q9NYV4 7/20 1.00
CCNA2 P20248 3/20 1.00
CCNE2 O96020 3/20 1.00
CCNA1 P78396 2/20 1.00
CDK1 P06493 13/20 0.89
CDK5 Q00535 9/20 0.89
CCNB1 P14635 7/20 0.89
CDK9 P50750 6/20 0.89
CDK7 P50613 6/20 0.89
CDK4 P11802 4/20 0.89
CCND1 P24385 4/20 0.89
CCNH P51946 4/20 0.89
CCNB2 O95067 4/20 0.89
CCNB3 Q8WWL7 4/20 0.89
DYRK1A Q13627 3/20 0.89
CCNT1 O60563 3/20 0.89
CDK5R1 Q15078 3/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13001898 1.00 CDK2 (1.00) CDK2CCNE1CCNKCDK12CCNA2
(S)-Roscovitine SCHEMBL2907488 0.94 CDK1 (1.00) CDK2CCNE1CCNKCDK12CCNA2
(S)-Roscovitine SCHEMBL29415376 0.94 CDK1 (1.00) CDK2CCNE1CCNKCDK12CCNA2
(Rs)-Roscovitine SCHEMBL172593 0.94 CDK1 (1.00) CDK2CCNE1CCNKCDK12CCNA2
Seliciclib SCHEMBL94728 0.94 CDK1 (1.00) CDK2CCNE1CCNKCDK12CCNA2
(Rs)-Roscovitine SCHEMBL15163619 0.94 CDK1 (1.00) CDK2CCNE1CCNKCDK12CCNA2
SCHEMBL13001902 0.90 CDK2 (1.00) CDK2CCNE1CCNKCDK12CCNA2
SCHEMBL29644968 0.90 CDK2 (1.00) CDK2CCNE1CCNKCDK12CCNA2
SCHEMBL9927174 0.90 CDK2 (1.00) CDK2CCNE1CCNKCDK12CCNA2
SCHEMBL13001905 0.90 CDK2 (1.00) CDK2CCNE1CCNKCDK12CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752629-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-08-25 US disclosed
US-10752629-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-08-25 US disclosed
US-20190084984-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-03-21 US disclosed
US-20190084984-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-03-21 US disclosed
US-10174031-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-01-08 US disclosed
US-10174031-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2019-01-08 US disclosed
US-20180009810-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-01-11 US disclosed
US-20180009810-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-01-11 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-9796714-B2 Calcium channel agonists University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2017-10-24 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed
US-20160090387-A1 CALCIUM CHANNEL AGONISTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009810-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK2 3024/4885CCNE1 4319/4885CCNK 3760/4885
US-20190084984-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK2 3024/4885CCNE1 4319/4885CCNK 3760/4885
US-20160090387-A1 CALCIUM CHANNEL AGONISTS CACNA1E, CACNA1C, CACNA1S CDK2 3024/4885CCNE1 4319/4885CCNK 3760/4885
US-10174031-B2 Calcium channel agonists CACNA1E, CACNA1C, CACNA1S CDK2 3024/4885CCNE1 4319/4885CCNK 3760/4885
US-10752629-B2 Calcium channel agonists CACNA1E, CACNA1C, CACNA1S CDK2 3024/4885CCNE1 4319/4885CCNK 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.